News
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...
Investor's Business Daily on MSN16h
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.
StockStory.org on MSN4d
The Top 5 Analyst Questions From Moderna’s Q1 Earnings CallModerna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback